Try our mobile app

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Published: 2024-03-25 12:00:00 ET
<<<  go to BMY company page

Analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF